IRVINE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on developing and commercializing therapies for patients with rare genetic mitochondrial diseases, announces today announced the appointment of Rossshawn Blunt to the company’s board of directors.
“Roshawn is an accomplished leader within the biopharmaceutical industry,” said Mike Gray, Executive Chairman of Reneo Pharmaceuticals. “His extensive experience in healthcare reimbursement, policy and patient access will be an invaluable addition to Reneo as we plan to commercialize REN001 in the US and Europe. We look forward to working with Rossshawn over the next few years,” concluded Mr. Grey.
“I am delighted to join Reneo’s Board of Directors,” said Ms. Blunt. “Reneo is an amazing company with a new drug that has the potential to treat a number of mitochondrial diseases. I look forward to working with the Board of Directors and supporting the management team.
Ms. Blunt has over 25 years of experience in the biopharmaceutical and medical device industries. She is president of Corsaire Corporation, a pharmaceutical marketing organization. Previously, Ms. Blunt was founder and CEO of 1798, LLC, a national healthcare consulting firm. Prior to starting 1798, Ms. Blunt was vice president of strategy, planning, and communications at Long Beach Memorial Center and Miller Children’s Hospital. She was the first global director of health economics and reimbursement for Biosense Webster, Inc., a Johnson & Johnson company. Ms. Blunt also held various strategic reimbursement and marketing positions at Amgen, Inc. She began her pharmaceutical career at the Boston Consulting Group, working primarily in the healthcare industry. Ms. Blunt is a graduate of Princeton University, where she received her AB from the Princeton School of Public and International Affairs, and holds an MBA from the Kellogg School of Management at Northwestern University.
About Reneo Pharmaceuticals
Reneo is a clinical-stage pharmaceutical company focused on developing and commercializing therapies for patients with rare mitochondrial genetic diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Our lead product candidate, REN001, is a potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist. REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria. For more information, please visit reneopharma.com.
Statements in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the development potential and commercialization of REN001. Because these statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by these forward-looking statements. Words such as ‘plans’, ‘will’, ‘believes’, ‘anticipates’, ‘expects’, ‘intends’, ‘aims’, ‘potential’ and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Reneo’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in these forward-looking statements due to various risks and uncertainties, which include, without limitation, the risks and uncertainties associated with Reneo’s business generally, and the other risks described in the documents. filed by Reneo with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Reneo undertakes no obligation to update these statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
LifeSci Advisors, LLC
Gregory J. Flesher
Chief executive officer
Reneo Pharmaceuticals, Inc.
Copyright 2022 GlobeNewswire, Inc.